Video Experimental Relacionado
Updated: Sep 9, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.7K
PSMD14 promueve la progresión del cáncer de mama reduciendo la ubiquitinación ligada a K63 en FOXM1 y activando la
Yuhan Liu1, Shichao Wen1, Wenmeng Wang2
1Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
International journal of biological macromolecules
|September 3, 2025
Resumen
La subunidad del proteasoma 26S PSMD14 impulsa la progresión del cáncer de mama al desbiquitar FOXM1 y activar la vía PI3K / AKT / mTOR. Esto pone de relieve PSMD14 como un objetivo terapéutico potencial para el tratamiento del cáncer de mama.
Área de la Ciencia:
- En el campo de la oncología
- Biología molecular
- La bioquímica
Sus antecedentes:
- La subunidad no reguladora de la ATPasa 26S (PSMD14), una enzima deubiquitinante (DUB), está implicada en varios tipos de cáncer.
- El papel específico y los mecanismos moleculares de PSMD14 en el cáncer de mama no se comprenden completamente.
Objetivo del estudio:
- Investigar el papel oncogénico de PSMD14 en el cáncer de mama.
- Para aclarar los mecanismos moleculares subyacentes a la función de PSMD14 en la progresión del cáncer de mama.
Principales métodos:
- Análisis de las bases de datos públicas para la expresión de PSMD14 y su valor pronóstico.
- Ensayos funcionales in vitro e in vivo (proliferación, migración y invasión).
- Ensayos de co-inmunoprecipitación, inmunofluorescencia y deubiquitinación para determinar los mecanismos moleculares, incluida la interacción con FOXM1 y la activación de la vía (PI3K/AKT/mTOR).
Principales resultados:
- La expresión elevada de PSMD14 se correlaciona con un mal pronóstico en pacientes con cáncer de mama.
- PSMD14 promueve significativamente la proliferación, la migración y la invasión de las células de cáncer de mama.
- El PSMD14 desbiquitina directamente el FOXM1 (vinculado al K63) y activa la vía PI3K/AKT/mTOR.
- PSMD14 aumenta la sensibilidad al tratamiento con cisplatino.
Conclusiones:
- PSMD14 promueve la progresión del cáncer de mama a través de la deubiquitinación de FOXM1 y la activación de la vía PI3K/ AKT/ mTOR.
- PSMD14 es un objetivo terapéutico potencial para la intervención del cáncer de mama.
Palabras clave:
Cáncer de mamaSensibilidad química al cisplatinoDesubicaciónEn el caso de los vehículos de motorLa vía PI3K/AKT/mTORPSMD14 (en inglés)Más Videos Relacionados
Videos de Conceptos Relacionados
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:19Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
01:07MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K